Xeris Pharmaceuticals Inc. (XERS) Misses Q1 EPS by 1c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $60.12 million versus the consensus estimate of $57.88 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2025 revenue of $260-270 million, versus the consensus of $262.3 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• JPMorgan Starts Computer Age Management Services (CAMS:IN ) at Overweight